Tipifarnib, a farnesyl transferase inhibitor, is a small molecule drug candidate that has demonstrated promising clinical activity in HRAS-mutant head and neck squamous cell carcinoma (HNSCC). Here, HRAS is linked to head and neck squamous cell carcinoma.